help@statsmarketresearch.com
Report Overview
Epidemic keratoconjunctivitis (EKC) is an infectious eye disease caused by viral infection. Its clinical features are rapid onset, conjunctival hyperemia, edema, many follicles, and punctate infiltration of corneal epithelial cells. The causative pathogen of this disease is adenovirus, and adenovirus type VIII is the most common, often causing outbreaks. Sufficient antiviral drugs, such as ganciclovir and acyclovir, should be given in the early stage of the disease to control the disease in time
www.reallygreatsite.com
Market Share
The global Epidemic Keratoconjunctivitis Treatment market size was estimated at USD 477.70 million in 2023 and is projected to reach USD 728.46 million by 2032, exhibiting a CAGR of 4.80% during the forecast period.
North America Epidemic Keratoconjunctivitis
Treatment market size was estimated at USD 134.93 million in 2023, at a CAGR of 4.11% during the forecast period of 2025 through 2032.
Key Company
• Sanofi S.A
• AbbVie Inc.
• Santen Pharmaceuticals Co. Ltd
• Japan Tobacco Inc.
• LeoPharma
• Incyte Corporation
• Renegeron
• Asana Biosciences
• Agio Pharmaceuticals Limited
• Synmedic Laboratories
Market Segmentation
• Topical
• Oral
By Application
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Geographic Segmentation
•North America: USA, Canada, Mexico
•Europe: Germany, UK, France, Russia, Italy, Rest of Europe
•Asia-Pacific: China, Japan, South Korea, India, SoutheastAsia, Rest ofAsia-Pacific
•South America: Brazil, Argentina, Colombia, Rest of SouthAmerica
•Middle East and Africa: Saudi Arabia, UAE, Egypt, Nigeria, SouthAfrica, Rest of MEA
